Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1227-1236

  Świa̧tkiewicz, Maciej ^a   Zaremba, Magorzata ^a   Joniec, Ilona ^a   Czonkowski, Andrzej ^a   Kurkowska Jastrzêbska, Iwona ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Ibuprofen; MPTP; Neurodegeneration; Neuroinflammation; Parkinson's disease; synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA SYNUCLEIN; HOMOVANILLIC ACID; IBUPROFEN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASAL GANGLIA; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IBUPROFEN; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84894191394     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71480-4     Document Type: Article

References (43)

1. Aid S, Bosetti F: Targeting cyclooxygenases -1 and -2 in neuroinflammation: therapeutic implications. Biochimie, 2011, 93, 46-51.
2. Asanuma M, Miyazaki I: Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol, 2007, 206, 172-178. (Pubitemid 47094768)
3. Asanuma M, Miyazaki I: Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurother, 2006, 6, 1313-1325. (Pubitemid 44580954)
4. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N: Neuroprotective effects of nonsteroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem, 2001, 76, 1895-1904. (Pubitemid 32221130)
5. Aubin N, Curet O, Deffois A, Carter C: Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem, 1998, 71, 1635-1642. (Pubitemid 28443036)
6. Barbiero JK, Santiago RM, Lima MM, Ariza D, Morais LH, Andreatini R, Vital MA: Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res, 2011, 216, 186-92.
7. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R: a-Synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic, 2009, 10, 218-234.
8. Bonini NM, Giasson BI: Snaring the function of a-synuclein. Cell, 2005, 123, 359-361.
9. Cabeza-Arvelaiz Y, Fleming SM, Richter F, Masliah E, Chesselet MF, Schiestl RH: Analysis of striatal transcriptome in mice overexpressing human wild-type alphasynuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol Neurodegener, 2011, 13, 83-99.
10. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B et al.: Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking a-synuclein. J Neurosci, 2002, 22, 8797-8807. (Pubitemid 35379049)
11. Carrasco E, Casper D, Werner P: Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res, 2005, 81, 121-131. (Pubitemid 41139117)
12. Carta AR, Pisanu A, Carboni E: Do PPAR-gamma agonists have a future in Parkinson's disease therapy? Parkinsons Dis, 2011, 2011, 689181.
13. Casper D, Yaparpalvi U, Rempel N, Werner P: Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett, 2000, 289, 201-204. (Pubitemid 30657973)
14. Chávez E, Castro-Sánchez L, Shibayama M, Tsutsumi V, Pérez Salazar E, Moreno MG, Muriel P: Effects of acetyl salycilic acid and ibuprofen in chronic liver damage induced by CCl4. J Appl Toxicol, 2012, 32, 51-59.
15. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol, 2005, 58, 963-967. (Pubitemid 41746889)
16. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol, 2003, 60, 1059-1064. (Pubitemid 36975791)
17. Chu CY, Liu YL, Chiu HC, Jee SH. Dopamine-induced apoptosis in humanmelanocytes involves generation of reactive oxygen species. Br J Dermatol, 2006, 154, 1071-1079.
18. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G: Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol, 2007, 205, 295-312. (Pubitemid 46778915)
19. Feng Z-H, Wang T-G, Li D-D, Fung P, Wilson BC, Liu B, Ali SF et al.: Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridineinduced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett, 2002, 329, 354-358. (Pubitemid 35245358)
20. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH: Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol, 1999, 360, 256-261. (Pubitemid 29480915)
21. Fortin DL, Nemani VM, Nakamura K, Edwards RH: The behavior of a-synuclein in neurons. Mov Disord, 2010, 25, Suppl 1, S21-26.
22. Gange JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease. A meta-analysis. Neurology, 2010 74, 995-1002.
23. Gao X, Chen H, Schwarzschild M, Ascherio A: Use of ibuprofen and risk of Parkinson disease. Neurology, 2011, 76, 863-869.
24. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K et al.: Acute treatment with the PPARg agonist pioglitazone and ibuprofen reduces glial inflammation and Ab1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453. (Pubitemid 40826196)
25. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol, 2009, 8, 382-397.
26. Hsieh YC, Mounsey RB, Teismann P: MPP+-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. Naunyn Schmiedebergs Arch Pharmacol, 2011, 384, 157-167.
27. Jiang C, Ting AT, Seed B: PPAR-g agonists inhibit production of monocyte inflamatory cytokines. Nature, 1998, 391, 82-86. (Pubitemid 28079219)
28. Kurkowska-Jastrzêbska I, Babiuch M, Joniec I, Przybykowski A, Czonkowski A, Czonkowska A: Indomethacin protects against nerodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol, 2002, 2, 1213-1218.
29. Kurkowska-Jastrzêbska I, Czonkowski A, Czonkowska A: Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol, 2006, 59, 988-989. (Pubitemid 43830934)
30. Madine J, Hughes E, Doig AJ, Middleton DA: The effects of a-synuclein on phospholipid vesicle integrity: a study using 31P NMR and electron microscopy. Mol Membr Biol, 2008, 25, 518-527.
31. Masana MI, Heyes MP, Mefford IN: Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge. Prog Neuropsychopharmacol Biol Psychiatry, 1990, 14, 609-621. (Pubitemid 20272352)
32. Milatovic D, Gupta RC, Yu Y, Zaja-Milatovic S, Aschner M: Protective effects of antioxidants and antiinflammatory agents against manganese-induced oxidative damage and neuronal injury. Toxicol Appl Pharmacol, 2011, 256, 219-226.
33. Miyamoto A, Hashiguchi Y, Obi T, Ishiguro S, Nishio A: Ibuprofen or ozagrel increases NO release and l-nitro arginine induces TXA2 release from cultured porcine basilar arterial endothelial cells. Vascul Pharmacol, 2007, 46, 85-90. (Pubitemid 44937686)
34. Mohanakumar KP, Muralikrishnan D, Thomas B: Neuroprotection sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res, 2000, 864, 281-290. (Pubitemid 30235109)
35. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ: The PPARg agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol, 2008, 154, 226-233. (Pubitemid 351620404)
36. Sairam K, Saravann K, Benerjee R, Mohanakumar KP: Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl-pyridinum-induced dopaminergic neurotoxicity in rats. Brain Res, 2003, 966, 245-252. (Pubitemid 36255587)
37. Stratman NC, Carter DB, Sethy VH: Ibuprofen: effect on inducible nitric oxide synthase. Brain Res Mol Brain Res, 1997, 50, 107-12 (Pubitemid 27488896)
38. Surguchov A: Synucleins: Are they two-edged swords? J Neurosci Res, 2012, 91, 161-166.
39. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA: The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal, 2011, 14, 1289-1301.
40. Swanson C, Joers V, Bondarenko V, Brunner K, Simmons H, Ziegler T, Kemnitz J et al.: The PPAR-g agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation, 2011, 8, 91.
41. Teismann P, Ferger B: Inhbition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP -mouse model of Parkinson's disease. Synapse, 2001, 39, 167-174. (Pubitemid 32104022)
42. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M et al.: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA, 2003, 100, 5473-5478. (Pubitemid 36542729)
43. Yang JL, Chen JS, Yang YF, Chen JC, Lin CH, Chang RS, Tsao PJ et al.: Neuroprotection effects of retained acupuncture in neurotoxin-induced Parkinson's disease mice. Brain Behavior Immun, 2011, 25, 1452-1459.